Last €2.93 EUR
Change Today +0.031 / 1.07%
Volume 0.0
PX9 On Other Exchanges
Symbol
Exchange
PX9 is not on other exchanges.
As of 2:56 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

pain therapeutics inc (PX9) Snapshot

Open
€2.93
Previous Close
€2.90
Day High
€2.93
Day Low
€2.93
52 Week High
06/27/14 - €4.36
52 Week Low
09/24/13 - €1.87
Market Cap
133.9M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
45.8M
EX-Date
12/13/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PAIN THERAPEUTICS INC (PX9)

pain therapeutics inc (PX9) Related Businessweek News

No Related Businessweek News Found

pain therapeutics inc (PX9) Details

Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs. Its lead drug candidate is REMOXY (oxycodone) Extended-Release Capsules CII, an investigational drug with a controlled release formulation of oxycodone for patients with moderate-to-severe chronic pain. The company’s other product candidates comprise hydromorphone, hydrocodone, and oxymorphone, which are abuse-resistant opioid product candidates. Pain Therapeutics, Inc. has strategic alliance with Pfizer, Inc. to develop and commercialize REMOXY and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in Austin, Texas.

8 Employees
Last Reported Date: 02/5/14
Founded in 1998

pain therapeutics inc (PX9) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $366.3K
Chief Operating Officer, Chief Medical Office...
Total Annual Compensation: $373.5K
Chief Scientific Officer
Total Annual Compensation: $323.5K
Compensation as of Fiscal Year 2013.

pain therapeutics inc (PX9) Key Developments

Pain Therapeutics Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Pain Therapeutics Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, operating loss was $3,257,000 against $319,000 a year ago. Net loss was $3,246,000 $0.07 per basic and diluted share against $301,000 $0.01 per basic and diluted share a year ago. For the six month, operating loss was $6,720,000 against $762,000 a year ago. Net loss was $6,695,000 $0.15 per basic and diluted share against $709,000 $0.02 per basic and diluted share a year ago.

Pain Therapeutics Inc., Q2 2014 Earnings Call, Aug 05, 2014

Pain Therapeutics Inc., Q2 2014 Earnings Call, Aug 05, 2014

Pain Therapeutics Inc.(NasdaqGS:PTIE) added to Russell 2000 Index

Pain Therapeutics Inc. will be added to the Russell 2000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PX9:GR €2.93 EUR +0.031

PX9 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PX9.
View Industry Companies
 

Industry Analysis

PX9

Industry Average

Valuation PX9 Industry Range
Price/Earnings 7.3x
Price/Sales 5.0x
Price/Book 4.3x
Price/Cash Flow 7.4x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAIN THERAPEUTICS INC, please visit www.paintrials.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.